Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Structural basis for broad detection of genogroup II noroviruses by a monoclonal antibody that binds to a site occluded in the viral particle.

Hansman GS, Taylor DW, McLellan JS, Smith TJ, Georgiev I, Tame JR, Park SY, Yamazaki M, Gondaira F, Miki M, Katayama K, Murata K, Kwong PD.

J Virol. 2012 Apr;86(7):3635-46. doi: 10.1128/JVI.06868-11. Epub 2012 Jan 25.

2.

Nanobody binding to a conserved epitope promotes norovirus particle disassembly.

Koromyslova AD, Hansman GS.

J Virol. 2015 Mar;89(5):2718-30. doi: 10.1128/JVI.03176-14. Epub 2014 Dec 17.

3.

Characterization of a broadly reactive monoclonal antibody against norovirus genogroups I and II: recognition of a novel conformational epitope.

Shiota T, Okame M, Takanashi S, Khamrin P, Takagi M, Satou K, Masuoka Y, Yagyu F, Shimizu Y, Kohno H, Mizuguchi M, Okitsu S, Ushijima H.

J Virol. 2007 Nov;81(22):12298-306. Epub 2007 Sep 12.

4.

Identification and characterization of antibody-binding epitopes on the norovirus GII.3 capsid.

Mahar JE, Donker NC, Bok K, Talbo GH, Green KY, Kirkwood CD.

J Virol. 2014 Feb;88(4):1942-52. doi: 10.1128/JVI.02992-13. Epub 2013 Nov 27.

5.

Crystal structures of GII.10 and GII.12 norovirus protruding domains in complex with histo-blood group antigens reveal details for a potential site of vulnerability.

Hansman GS, Biertümpfel C, Georgiev I, McLellan JS, Chen L, Zhou T, Katayama K, Kwong PD.

J Virol. 2011 Jul;85(13):6687-701. doi: 10.1128/JVI.00246-11. Epub 2011 Apr 27.

6.

Multiple antigenic sites are involved in blocking the interaction of GII.4 norovirus capsid with ABH histo-blood group antigens.

Parra GI, Abente EJ, Sandoval-Jaime C, Sosnovtsev SV, Bok K, Green KY.

J Virol. 2012 Jul;86(13):7414-26. doi: 10.1128/JVI.06729-11. Epub 2012 Apr 24.

7.

Immunogenetic mechanisms driving norovirus GII.4 antigenic variation.

Lindesmith LC, Beltramello M, Donaldson EF, Corti D, Swanstrom J, Debbink K, Lanzavecchia A, Baric RS.

PLoS Pathog. 2012;8(5):e1002705. doi: 10.1371/journal.ppat.1002705. Epub 2012 May 17.

9.

Identification of human single-chain antibodies with broad reactivity for noroviruses.

Huang W, Samanta M, Crawford SE, Estes MK, Neill FH, Atmar RL, Palzkill T.

Protein Eng Des Sel. 2014 Oct;27(10):339-49. doi: 10.1093/protein/gzu023. Epub 2014 Jun 19.

10.

Mapping broadly reactive norovirus genogroup I and II monoclonal antibodies.

Crawford SE, Ajami N, Parker TD, Kitamoto N, Natori K, Takeda N, Tanaka T, Kou B, Atmar RL, Estes MK.

Clin Vaccine Immunol. 2015 Feb;22(2):168-77. doi: 10.1128/CVI.00520-14. Epub 2014 Nov 26.

11.

Characterization of a cross-reactive monoclonal antibody against Norovirus genogroups I, II, III and V.

Li X, Zhou R, Tian X, Li H, Zhou Z.

Virus Res. 2010 Aug;151(2):142-7. doi: 10.1016/j.virusres.2010.04.005. Epub 2010 Apr 24.

PMID:
20417671
12.

Genogroup IV and VI canine noroviruses interact with histo-blood group antigens.

Caddy S, Breiman A, le Pendu J, Goodfellow I.

J Virol. 2014 Sep;88(18):10377-91. doi: 10.1128/JVI.01008-14. Epub 2014 Jul 9.

13.

Biological and immunological characterization of norovirus major capsid proteins from three different genotypes.

Huo Y, Wan X, Ling T, Shen S.

Microb Pathog. 2016 Jan;90:78-83. doi: 10.1016/j.micpath.2015.11.022. Epub 2015 Nov 23.

PMID:
26616166
14.

Characterization of cross-reactive norovirus-specific monoclonal antibodies.

Kou B, Crawford SE, Ajami NJ, Czakó R, Neill FH, Tanaka TN, Kitamoto N, Palzkill TG, Estes MK, Atmar RL.

Clin Vaccine Immunol. 2015 Feb;22(2):160-7. doi: 10.1128/CVI.00519-14. Epub 2014 Nov 26.

15.

Particle conformation regulates antibody access to a conserved GII.4 norovirus blockade epitope.

Lindesmith LC, Donaldson EF, Beltramello M, Pintus S, Corti D, Swanstrom J, Debbink K, Jones TA, Lanzavecchia A, Baric RS.

J Virol. 2014 Aug;88(16):8826-42. doi: 10.1128/JVI.01192-14. Epub 2014 May 28.

16.

Structural analysis of bovine norovirus protruding domain.

Singh BK, Koromyslova A, Hansman GS.

Virology. 2016 Jan;487:296-301. doi: 10.1016/j.virol.2015.10.022. Epub 2015 Nov 18.

17.

Anti-norovirus polyclonal antibody and its potential for development of an antigen-ELISA.

Okame M, Shiota T, Hansman G, Takagi M, Yagyu F, Takanashi S, Phan TG, Shimizu Y, Kohno H, Okitsu S, Ushijima H.

J Med Virol. 2007 Aug;79(8):1180-6.

PMID:
17596835
18.

Flexibility in surface-exposed loops in a virus capsid mediates escape from antibody neutralization.

Kolawole AO, Li M, Xia C, Fischer AE, Giacobbi NS, Rippinger CM, Proescher JB, Wu SK, Bessling SL, Gamez M, Yu C, Zhang R, Mehoke TS, Pipas JM, Wolfe JT, Lin JS, Feldman AB, Smith TJ, Wobus CE.

J Virol. 2014 Apr;88(8):4543-57. doi: 10.1128/JVI.03685-13. Epub 2014 Feb 5.

19.

Chimeric GII.4 norovirus virus-like-particle-based vaccines induce broadly blocking immune responses.

Debbink K, Lindesmith LC, Donaldson EF, Swanstrom J, Baric RS.

J Virol. 2014 Jul;88(13):7256-66. doi: 10.1128/JVI.00785-14. Epub 2014 Apr 16.

20.

Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity.

Debbink K, Donaldson EF, Lindesmith LC, Baric RS.

J Virol. 2012 Jan;86(2):1214-26. doi: 10.1128/JVI.06189-11. Epub 2011 Nov 16.

Supplemental Content

Support Center